HIV integrase: The next target?

Infections in Medicine

Volumn 15, Issue 2, 1998, Pages 129-137

  Robinson Jr , W Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV integrase; Human immunodeficiency virus (HIV); Therapy, AIDS

Indexed keywords

AURINTRICARBOXYLIC ACID; DNA POLYMERASE; DOXORUBICIN; GENE PRODUCT; INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CATALYSIS; DRUG POTENCY; ENZYME INHIBITION; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GENOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; VIRUS REPLICATION;

EID: 13144275199     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Clumeck N: Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother 32(suppl A):S133-S138, 1993.
2. Cooper DA, Group E-AC: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 329:297-303, 1993.
3. Hirsch MS: Chemotherapy of human immunodeficiency virus infections: Current practice and future prospects. J Infect Dis 161:845-857, 1990.
4. Volberding PA, ACTG-NIAID: Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 322:941-949, 1990.
5. Aboulker J, Swart AM: Preliminary analysis of the Concorde trial. Lancet i:889-890, 1993.
6. Caliendo AM, Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 18:516-524, 1994.
7. Rooke R, Parniak MA, Tremblay M, et al: Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: Susceptibility and resistance to other drugs. Antimicrob Agents Chemother 35:988-991, 1991.
8. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734, 1989.
9. Johnson VA, Merrill DP, Chou TC, et al: Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 166:1143-1146, 1992.
10. Pollard RB: Use of proteinase inhibitors in clinical practice. Pharmacotherapy 14 (suppl):S21-S29, 1994.
11. 2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 36:926-933, 1992.
12. Alteri E, Bold G, Cozens R, et al: CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother 37:2087-2092, 1993.
13. Kuzmic P, Garcia-Echeverria C, Rich DH: Stabilization of HIV proteinase dimer by bound substrate. Biochem Biophys Res Commun 194:301-305, 1993.
14. Chen Z, Li Y, Chen E, et al: Crystal structure at 1.9-Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem 269:26344-26348, 1994.
15. Kageyama S, Mimoto T, Murakawa Y, et al: In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother 37:810-817, 1993.
16. Maschera B, Furfine E, Blair ED: Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 69:5431-5436, 1995.
17. Partaledis JA, Yamaguchi K, Tisdale M, et al: In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylaminosulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69:5228-5235, 1995.
18. Gulnik SV, Suvorov LI, Liu B, et al: Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287, 1995.
19. Swanstrom R: Characterization of HIV-1 protease mutants: Random, directed, selected. Curr Opin Biotechnol 5:409-413, 1994.
20. Baldwin ET, Bhat TN, Liu B, et al: Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat Struct Biol 2:244-249, 1995.
21. Turriziani O, Antonelli G, Jacobsen H, et al: Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 38:297-298, 1994.
22. Culberson JC, Bush BL, Sardana VV: Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis. Methods Enzymol 241:385-394, 1994.
23. Ho DD, Toyoshima T, Mo H, et al: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 68:2016-2020, 1994.
24. Otto MJ, Garber S, Winslow DL, et al: In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A 90:7543-7547, 1993.
25. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995.
26. Tisdale M, Myers RE, Maschera B, et al: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 39:1704-1710, 1995.
27. LaFemina RL, Schneider CL, Robbins HL, et al: Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 66:7414-7419, 1992.
28. Sakai H, Kawamura M, Sakuragi J, et al: Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 67:1169-1174, 1993.
29. Shin CG, Taddeo B, Haseltine WA, et al: Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol 68:1633-1642, 1994.
30. Engelman A, Englund G, Orenstein JM, et al: Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 69:2729-2736, 1995.
31. Roth MJ, Schwartzberg P, Tanese N, et al: Analysis of mutations in the integration function of Moloney murine leukemia virus: Effect on DNA binding and cutting. J Virol 64:4709-4717, 1990.
32. Bowerman B, Brown PO, Bishop JM, et al: A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 3:469-478, 1989.
33. Bukrinsky MI, Sharova N, McDonald TL, et al: Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A 90:6125-6129, 1993.
34. Heinzinger NK, Burkinsky MI, Haggerty SA, et al: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 91:7311-7315, 1994.
35. Roe TY, Reynolds TC, Yu G, et al: Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099-2108, 1993.
36. Kulkosky J, Jones KS, Katz RA, et al: Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 12:2331-2338, 1992.
37. Taddeo B, Haseltine WA, Farnet CM: Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J Virol 68:8401-8405, 1994.
38. Stevenson M, Stanwick TL, Dempsey MP, et al: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9:1551-1560, 1990.
39. Cannon PM, Wilson W, Byles E, et al: Human immunodeficiency virus type 1 integrase: Effect on viral replication of mutations at highly conserved residues. J Virol 68:4768-4775, 1994.
40. Varmus HE, Brown PO: Retroviruses, in Howe M, Berg D (eds): Mobile DNA. Washington, DC, American Society for Microbiology, 1989, pp 53-108.
41. Shiramizu B, Herndier BG, McGrath MS: Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res 54:2069-2072, 1994.
42. Vink C, Plasterk RH: The human immunodeficiency virus integrase protein. Trends Genet 9:433-438, 1993.
43. Ellison V, Abrams H, Roe T, et al: Human immunodeficiency virus integration in a cell-free system. J Virol 64:2711-2715, 1990.
44. Chow SA, Vincent KA, Ellison V, et al: Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 255:723-726, 1992.
45. Chow SA, Brown PO: Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J Virol 68:3896-3907, 1994.
46. Johnson MS, McClure MA, Feng D-F, et al: Computer analysis of retroviral pol genes: Assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci U S A 83:7648-7652, 1986.
47. Kahn E, Mack JPG, Katz RA, et al: Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res 19:851-860, 1991.
48. Engelman A, Craigie R: Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. J Virol 69:5908-5911, 1995.
49. Pemberton IK, Buckle M, Buc H: The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn++ rather than Mg++. J Biol Chem 271:1498-1506, 1996.
50. Leavitt AD, Shiue L, Varmus HE: Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Biol Chem 268:2113-2119, 1993.
51. Engelman A, Craigie R: Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 66:6361-6369, 1992.
52. Vink C, Oude Groeneger AM, Plasterk RH: Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res 21:1419-1425, 1993.
53. Berg JM: Zinc fingers and other metal-binding domains. J Biol Chem 265:6513-6516, 1990.
54. Vincent KA, Ellison V, Chow SA, et al: Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J Virol 67:425-437, 1993.
55. Ellison V, Brown PO: A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci U S A 91:7316-7320, 1994.
56. 2+-dependent 3′-processing activity of human immunodeficiency virus type 1 integrase in vitro. Biochemistry 35:3837-3844, 1996.
57. Woerner AM, Klutch M, Levin JG, et al: Localization of DNA binding activity of HIV-1 integrase to the C-terminal half of the protein. AIDS Res Hum Retroviruses 8:297-304, 1992.
58. Engelman A, Hickman AB, Craigie R: The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to non-specific DNA binding. J Virol 68:5911-5917, 1994.
59. Cannon PM, Byles ED, Kingsman SM, et al: Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol 70:651-657, 1996.
60. Hickman AB, Palmer I, Engelman A, et al: Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase. J Biol Chem 269:29279-29287, 1994.
61. Bujacz G, Jaskolski M, Alexandratos J, et al: The catalytic domain of avian sarcoma virus integrase: Conformation of the active-site residues in the presence of cations. Structure 4:89-96, 1996.
62. Dyda F, Hickman AB, Jenkins TM, et al: Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 266:1981-1986, 1994.
63. Lodi PJ, Ernst JA, Kuszewski J, et al: Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34:9826-9833, 1995.
64. Lutzke RAP, Vink C, Plasterk RH: Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res 22:4125-4131, 1994.
65. Ho DD, Neumann AU, Perelson AS, et al: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126, 1995.
66. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122, 1995.
67. Richman DD, Havlir D, Corbeil J, et al: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68:1660-1666, 1994.
68. Fesen MR, Kohn KW, Leteurtre F, et al: Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 90:2399-2403, 1993.
69. Billich A, Schauer M, Frank S, et al: HIV integrase: High-level production and screening assay for the endonucleolytic activity. Antiviral Chem Chemother 3:113-119, 1992.
70. Carteau S, Mouscadet JF, Goulaouic H, et al: Inhibition of the in vitro integration of Moloney murine leukemia virus DNA by the DNA minor groove binder netropsin. Biochem Pharmacol 47:1821-1826, 1994.
71. Cushman M, Golebiewski WM, Pommier Y, et al: Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J Med Chem 38:443-452, 1995.
72. Cushman M, Sherman P: Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem Biophys Res Commun 185:85-90, 1992.
73. Fesen MR, Pommier Y, Leteurtre F, et al: Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 48:595-608, 1994.
74. LaFemina RL, Graham PL, LeGrow K, et al: Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob Agents Chemother 39:320-324, 1995.
75. Burke TR, Fesen MR, Mazumder A: Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem 38:4171-4178, 1995.
76. Farnet CM, Wang B, Lipford JR, et al: Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc Natl Acad Sci U S A 93:9742-9747, 1996.
77. Mazumder A, Gazit A, Levitzki A, et al: Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 34:15111-15122, 1995.
78. Mazumder A, Wang S, Neamati N, et al: Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J Med Chem 39:2472-2481, 1996.
79. Mazumder A, Cooney D, Agbaria R, et al: Inhibition of human immunodeficiency virus type 1 integrase by 3′-azido-3′-deoxythymidylate. Proc Natl Acad Sci U S A 91:5771-5775, 1994.
80. Mazumder A, Neamati N, Sommadossi JP, et al: Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol Pharmacol 49:621-628, 1996.
81. Ojwang JO, Buckheit RW, Pommier Y, et al: T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 39:2426-2435, 1995.
82. Abrams D, Cotton D, Markowitz M, et al: AR-177 (Zintevir): AIDS/HIV Treatment Directory. New York, AmFAR, 1996, pp 50-51.
83. Abdel-Malek S, Bastien JW, Mahler WF, et al: Drug leads from the Kallawaya herbalists of Bolivia, 1: Background, rationale, protocol and anti-HIV activity. J Ethnopharmacol 50:157-166, 1996.
84. Robinson WE, Jr, Reinecke MG, Abdel-Malek S, et al: Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci U S A 93:6326-6331, 1996.
85. Mahmood N, Moore PS, De Tommasi N, et al: Inhibition of HIV infection by caffeoylquinic acid derivatives. Antiviral Chem Chemother 4:235-240, 1993.
86. Robinson WE, Jr, Cordeiro M, Abdel-Malek S, et al: Dicaffeoylquinic acid inhibitors of human immunodeficiency virus (HIV) integrase: Inhibition of the core catalytic domain of HIV integrase. Mol Pharmacol 50:846-855, 1996.
87. McDougall BR, King PJ, Wu BW, et al: Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 42:140-146, 1998.
88. Hong H, Neamati N, Wang S, et al: Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 40:930-936, 1998.
89. Nicklaus MC, Neamati N, Hong H, et al: HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J Med Chem 40:920-929, 1997.
90. Neamati N, Hong H, Mazumder A, et al: Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3 D database searching. J Med Chem 40:942-951, 1998.
91. Zhao H, Neamati, Hong H, et al: Coumarin-based inhibitors of HIV integrase. J Med Chem 40:242-249, 1997.
92. Zhao H, Neamati N, Sunder S, et al: Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem 40:937-941, 1997.
93. Zhao H, Neamati N, Mazumder A, et al: Arylamide inhibitors of HIV-1 integrase. J Med Chem 40:1186-1194, 1997.
94. Craigie R, Mizuuchi K, Bushman FD, et al: A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res 19:2629-2734, 1991.
95. Bushman FD, Fujiwara T, Craigie R: Retroviral DNA integration directed by HIV integration protein in vitro. Science 249:1555-1558, 1990.
96. Farnet CM, Haseltine WA: Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 65:1910-1915, 1991.